Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient

Mantle cell lymphoma (MCL) accounts for approximately 3–6% of all Non-Hodgkin Lymphomas (NHL). Patients’ median age at diagnosis is 68 years [1] with male predominance and median survival of 4–5 ye...